Nayar R - Search Results

1

Feasibility of tissue plasminogen activator formulated for pulmonary delivery.

Dunn JS, Nayar R, Campos J, Hybertson BM, Zhou Y, Manning MC, Repine JE, Stringer KA. Dunn JS, et al. Among authors: nayar r. Pharm Res. 2005 Oct;22(10):1700-7. doi: 10.1007/s11095-005-6335-8. Epub 2005 Sep 22. Pharm Res. 2005. PMID: 16180128 Free PMC article.

2

Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice.

Stringer KA, Tobias M, Dunn JS, Campos J, Van Rheen Z, Mosharraf M, Nayar R. Stringer KA, et al. Among authors: nayar r. Clin Exp Pharmacol Physiol. 2008 Dec;35(12):1454-60. doi: 10.1111/j.1440-1681.2008.05011.x. Epub 2008 Jul 29. Clin Exp Pharmacol Physiol. 2008. PMID: 18671720 Free PMC article.

3

Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice.

Lackowski NP, Pitzer JE, Tobias M, Van Rheen Z, Nayar R, Mosharaff M, Stringer KA. Lackowski NP, et al. Among authors: nayar r. Pulm Pharmacol Ther. 2010 Apr;23(2):107-14. doi: 10.1016/j.pupt.2009.10.009. Epub 2009 Oct 29. Pulm Pharmacol Ther. 2010. PMID: 19879371 Free PMC article.

4

High throughput formulation: strategies for rapid development of stable protein products.

Nayar R, Manning MC. Nayar R, et al. Pharm Biotechnol. 2002;13:177-98. doi: 10.1007/978-1-4615-0557-0_8. Pharm Biotechnol. 2002. PMID: 11987752 Review. No abstract available.

5

Infrared spectroscopic studies of protein formulations containing glycine.

Meyer JD, Jun Bai S, Rani M, Suryanarayanan R, Nayar R, Carpenter JF, Manning MC. Meyer JD, et al. Among authors: nayar r. J Pharm Sci. 2004 May;93(5):1359-66. doi: 10.1002/jps.20019. J Pharm Sci. 2004. PMID: 15067711

6

Noninvasive determination of protein conformation in the solid state using near infrared (NIR) spectroscopy.

Bai S, Nayar R, Carpenter JF, Manning MC. Bai S, et al. Among authors: nayar r. J Pharm Sci. 2005 Sep;94(9):2030-8. doi: 10.1002/jps.20416. J Pharm Sci. 2005. PMID: 16052558

7

Solution behavior of a novel type 1 interferon, interferon-tau.

Katayama DS, Nayar R, Chou DK, Campos J, Cooper J, Vander Velde DG, Villarete L, Liu CP, Cornell Manning M. Katayama DS, et al. Among authors: nayar r. J Pharm Sci. 2005 Dec;94(12):2703-15. doi: 10.1002/jps.20461. J Pharm Sci. 2005. PMID: 16258985

8

Impact of bulking agents on the stability of a lyophilized monoclonal antibody.

Meyer JD, Nayar R, Manning MC. Meyer JD, et al. Among authors: nayar r. Eur J Pharm Sci. 2009 Aug 12;38(1):29-38. doi: 10.1016/j.ejps.2009.05.008. Epub 2009 May 23. Eur J Pharm Sci. 2009. PMID: 19467324

9

Quantification of glycine crystallinity by near-infrared (NIR) spectroscopy.

Bai SJ, Rani M, Suryanarayanan R, Carpenter JF, Nayar R, Manning MC. Bai SJ, et al. Among authors: nayar r. J Pharm Sci. 2004 Oct;93(10):2439-47. doi: 10.1002/jps.20153. J Pharm Sci. 2004. PMID: 15349954

10

Effect of buffer species on the thermally induced aggregation of interferon-tau.

Katayama DS, Nayar R, Chou DK, Valente JJ, Cooper J, Henry CS, Vander Velde DG, Villarete L, Liu CP, Manning MC. Katayama DS, et al. Among authors: nayar r. J Pharm Sci. 2006 Jun;95(6):1212-26. doi: 10.1002/jps.20471. J Pharm Sci. 2006. PMID: 16637050

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

331 results

Search Page

Filters